Key result
Periconceptional folic acid protects against congenital heart defects, though optimal timing and dosing remain unclear.
Why the study?
Evidence on risk factors for developmental defects resulting from drug use before conception and during pregnancy is still very limited, and the dose and timing of folic acid supplementation for preventing congenital heart diseases are not well established.
Does folic acid supplementation before and during pregnancy prevent congenital heart diseases in infants?
Does folic acid supplementation before and during pregnancy prevent congenital heart diseases in infants?
This review confirms the protective effect of periconceptional folic acid supplementation against congenital heart diseases, highlighting the need for further research on optimal dosing and timing.
Supports periconceptional folic acid to lower CHD risk; reinforces guidelines and extends evidence to cardiac malformations.
Background: Folate is essential for metabolism and development. So, folate metabolism abnormalities are common in infants with some congenital defects. An infant born to mothers with normal folate status has more resistant to congenital heart diseases (CHDs). Evidence on risk factors for developmental defects resulting from drug use before conception and during pregnancy is still very limited. The relationship between folic acid for mothers before and throughout pregnancy and the incidence of fetal malformations and diseases have been recognized. Aims: This article is a rapid review for assessment of the folic acid supplementation as a preventive measure of CHDs during fetal development, and what is already recognized about a policy of this subject, by using systematic review methods to search some of the existing researches. Materials: publications related to determining and quantifying the use of folate by pregnant mothers to decrease the risk of congenital heart diseases were reviewed. Many studies have confirmed the reduction of congenital heart diseases by folic acid supplementation prior to pregnancy. Conclusion: the protective effect of folic acid against congenital heart abnormalities has been established. Though, the dose and time of supplementation are not known; more researches are needed to explain the mechanisms.
No takes yet. Share an insight, caveat, or question.
Mazin Mahmoud Fawzi (2021) conducted a review in Congenital heart diseases. Folic acid supplementation was evaluated on Congenital heart diseases. Periconceptional folic acid supplementation has an established protective effect against congenital heart abnormalities, though optimal dosing and timing remain unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: